Saeed Sadia, Keehn Connie A, Morgan Michael B
Department of Pathology, University of South Florida College of Medicine, Tampa, FL, USA.
J Cutan Pathol. 2004 Jul;31(6):419-30. doi: 10.1111/j.0303-6987.2004.00207.x.
Cutaneous tumor metastasis may be the first manifestation of cancer, but more often is a harbinger of advanced disease that portends an ominous prognosis. All skin accessions over the past 10 years from a large Veterans Administration (VA) hospital were reviewed.
Archived histories, glass slides, and the immunohistochemical battery (IHC), were assessed to determine diagnostic accuracy.
Of the 100,453 cases reviewed, there were a total of 77 cases (75 males and 2 females) of cutaneous metastasis from the lungs (28.6%), metastatic melanoma (18.2%), gastrointestinal tract (14.2%), genitourinary tract (10.4%), head and neck (9.1%), hematologic (5.2%), breast (5.2%), and miscellaneous (<2%). Metastasis represented the first indication of an internal malignancy in 7.8% of cases. The cutaneous sites of involvement included the head and neck (28%), the trunk (40%), the extremities (18%), and multiple sites (14%). The age range was 38-83 years, with a mean of 62 years. The average time interval between diagnosis of internal malignancy and cutaneous presentation was 33 months (range: <1 month-22 years), and the average survival following diagnosis was 7.5 months (range: <1 month-8 years). In a cohort of subjects, a truncated immunohistochemical battery consisting of CK-7, CK-20, and S-100 was consistent with the expected staining pattern of the primary source of cutaneous metastasis in 83.33% of the patients.
Excluding the potential for age and gender bias in this study conducted in a VA setting, cutaneous metastases represent an uncommon, deadly, and late-developing occurrence in many patients. Compared with previous studies, lung carcinoma remains the most common of the cutaneous metastases, with a relative rise in the incidence of metastatic melanoma. The immunohistochemical battery of CK-7, CK-20, and S-100 is a helpful adjunct in narrowing the differential diagnosis of the primary site of a large proportion of cutaneous metastases, particularly tumors with an epithelioid appearance such as carcinomas and melanomas.
皮肤肿瘤转移可能是癌症的首发表现,但更常见的是晚期疾病的先兆,预示着预后不良。回顾了一家大型退伍军人管理局(VA)医院过去10年的所有皮肤病例。
评估存档的病史、玻片和免疫组织化学检测组合(IHC),以确定诊断准确性。
在审查的100453例病例中,共有77例(75例男性和2例女性)皮肤转移癌,其原发部位分别为肺(28.6%)、转移性黑色素瘤(18.2%)、胃肠道(14.2%)、泌尿生殖道(10.4%)、头颈部(9.1%)、血液系统(5.2%)、乳腺(5.2%)和其他(<2%)。转移是7.8%病例中内部恶性肿瘤的首发迹象。皮肤受累部位包括头颈部(28%)、躯干(40%)、四肢(18%)和多个部位(14%)。年龄范围为38 - 83岁,平均年龄为62岁。内部恶性肿瘤诊断与皮肤表现之间的平均时间间隔为33个月(范围:<1个月 - 22年),诊断后的平均生存期为7.5个月(范围:<1个月 - 8年)。在一组受试者中,由细胞角蛋白7(CK - 7)、细胞角蛋白20(CK - 20)和S - 100组成的简化免疫组织化学检测组合与83.33%患者皮肤转移原发部位的预期染色模式一致。
在这家VA医院进行的这项研究中,排除年龄和性别偏见的可能性后,皮肤转移在许多患者中是一种罕见、致命且出现较晚的情况。与先前的研究相比,肺癌仍然是最常见的皮肤转移癌,转移性黑色素瘤的发病率相对上升。CK - 7、CK - 20和S - 100的免疫组织化学检测组合有助于缩小大部分皮肤转移癌原发部位的鉴别诊断范围,特别是对于具有上皮样外观的肿瘤,如癌和黑色素瘤。